Generic placeholder image

Current Topics in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1568-0266
ISSN (Online): 1873-4294

Non-Camptothecin DNA Topoisomerase I Inhibitors in Cancer Therapy

Author(s): Meng Ling-hua, Liao Zhi-yong and Yves Pommier

Volume 3, Issue 3, 2003

Page: [305 - 320] Pages: 16

DOI: 10.2174/1568026033452546

Price: $65

Abstract

Human DNA topoisomerase I is the target of camptothecins, which have been recently introduced in the clinic for cancer chemotherapy. The discovery of novel noncamptothecin inhibitors is facilitated by the availability of biochemical and cellular assays for testing topoisomerase I activity. Among the non-camptothecin inhibitors, the indolocarbazoles (NB-506 and J-107088) are the most advanced in their development, and are in clinical trials. A number of indenoisoquinolines and minor groove binders (benzimidazoles) have been reported recently. Their antitumor activity is promising for further development. The potential binding site(s) of topoisomerase I inhibitors in the enzyme I-DNA complex is discussed.

Keywords: dna topoisomerases, topoisomerase II, anticancer drugs, dna cleavage, dna ligation, dna cleavage complex


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy